Development of Epalrestat (Kinedak): Aldose Reductase Inhibitor.
- 1 January 1997
- journal article
- research article
- Published by The Society of Synthetic Organic Chemistry, Japan in Journal of Synthetic Organic Chemistry, Japan
- Vol. 55 (7) , 651-657
- https://doi.org/10.5059/yukigoseikyokaishi.55.651
Abstract
It is believed that the aldose reductase (AR, EC 1.1.21), the initial enzyme of sorbitol pathway, plays a significant role in the initiation of diabetic complications. In a search for AR inhibitors, a series of 4-oxo-2-thioxothiazolidine-3-acetic acid derivatives was synthesized and showed the inhibitory activity against AR. (Z, E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxothiazolidine-3-acetid acid (epalrestat) prevented the accumulation of sorbitol in rat sciatic nerve and rat blood cell, and improved motor nerve conduction velocity of diabetic rats. In clinical studies, epalrestat has shown the improvements in nerve function and subjective symptoms. In Japan, epalrestat was introduced on the market in January, 1992.Keywords
This publication has 4 references indexed in Scilit:
- Aldose reductase inhibitors and their potential for the treatment of diabetic complicationsTrends in Pharmacological Sciences, 1994
- The Aldose Reductase ControversyDiabetes, 1994
- EFFECTS OF A NEW ALDOSE REDUCTASE INHIBITOR ON VARIOUS TISSUES INVITRO1984
- Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic ratsDiabetologia, 1983